Real-life data on clinical characteristics, treatments and outcomes of patients with newly diagnosed advanced-stage ovarian cancer: an observational study from Belgium

Until 2018, surgical resection followed by first-line chemotherapy and bevacizumab use comprised the cornerstone therapy for newly diagnosed FIGO stage IV OC in Belgium. Clinical response and progression-free survival rates were relatively high. The patients' <i>BRCA1/BRCA2</i> status was insufficiently characterized, likely reflecting the lack of perceived relevance of <i>BRCA1/BRCA2</i> mutations for OC treatment before adoption of targeted therapies in clinical practice.